407294

αA-Interferon, Human, Recombinant, E. coli

• Synonym(s): IFNA2A, IFNA2B, IFNA2C, rhIFN-αA
• NACRES: NA.77
• UNSPSC Code: 12352202
• Form: liquid
• Assay: ≥95% (SDS-PAGE)

Properties

• description: Merck USA index - 14, 4990
• Quality Segment: 100
• assay: ≥95% (SDS-PAGE)
• form: liquid
• specific activity: ≥2.8 x 10⁸ units/mg protein, ≥5 x 10⁶ units/mL
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, avoid repeated freeze/thaw cycles
• technique(s): cell based assay: suitable
• solubility: soluble (Dilute only in buffers containing protein such as 0.1% BSA.)
• NCBI accession no.: NM_000605.4
• UniProt accession no.: P01563
• shipped in: wet ice
• storage temp.: −70°C
• Gene Information: human ... IFNA1(3340)

Description

General description

Research area: Immunoand cks

Interferons are cytokines secreted by mammalian cells. They are broadly divided into type I– interferon alpha (IFN-α) and interferon beta (IFN-β), type II – interferon-gamma (IFN-γ), and type III – interferon lambda (IFN-λ) based on their structure, function, and receptor specificity. Recombinant αA interferon is a hydrophobic protein belonging to the IFN-α family of proteins.

Application

Interferon alpha has been used to evaluate its effect on VSV (vesicular stomatitis virus) infection in pancreatic ductal adenocarcinoma (PDA) cell lines and study the relationship between type I IFNsignaling, resistance to VSV infection, and the JAK/STAT (Janus kinase/signal transducers and activators of transcription) signaling pathways in PDA cell lines. It has also been used to study the inhibitory effect of Morbillivirus V Proteins on Interferon Signaling Pathways.

Biochem/physiol Actions

Recombinant, human αA-interferon expressed in E. coli have antiviral, antiproliferative, antineoplastic, and immunomodulating properties. Recombinant interferon αA (IFN-αA) is used as the first line of treatment for hepatitis C. It also displays a great therapeutic potential with chronic viral hepatitis, polycythemia, leukemia, and various other malignancies. It enhances natural killer cell activity, suppresses bone marrow function, and induces apoptotic cell death in non-melanoma skin cancer.

Physical form

In PBS containing 0.1% BSA.

Preparation Note

Dilute only in buffers containing protein such as 0.1% BSA.

Following initial thaw, aliquot and freeze (-70°C).

Other Notes

Fujishima, H., et al. 1998. Int. J. Cancer 76, 423.
Haria, M., and Benfield, P. 1995. Drugs 50, 873.
Familletti, P.C., et al. 1981. Methods Enzymol. 78, 387.

One unit of interferon per ml of medium will cause a 50% inhibition of VSV-induced cytopathic effect on bovine MDBK cells. Units are determined with respect to the NIH international reference standard for human αA-IFN. Dilute in aqueous buffer containing at least 0.1% BSA or HSA.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Safety Information

• Storage Class: 10 - Combustible liquids
• wgk: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable